1. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
- Author
-
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, and Lyles KW
- Subjects
- Absorptiometry, Photon, Aged, Bone Density drug effects, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hip Fractures epidemiology, Humans, Incidence, Injections, Intravenous, Male, Osteoporosis diagnosis, Osteoporosis epidemiology, Prevalence, Time Factors, Treatment Outcome, Zoledronic Acid, Bone Density Conservation Agents administration & dosage, Diphosphonates administration & dosage, Hip Fractures prevention & control, Imidazoles administration & dosage, Osteoporosis drug therapy
- Abstract
Objectives: To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once- Yearly Recurrent Fracture Trial and to compare the efficacy with that in women from the same study., Design: Randomized, placebo-controlled, double-blind trial., Setting: International multicenter., Participants: Five hundred and eight men and 1,619 women within 90 days of surgical repair of low-trauma hip fracture in the same study (for comparison)., Intervention: Once-yearly intravenous (IV) ZOL 5 mg (n = 248) or placebo (n = 260), loading dose of vitamin D, daily calcium, and vitamin D supplements., Measurement: Changes in BMD., Results: Percentage change from baseline in total hip BMD at Months 12 and 24 was significantly higher with ZOL than with placebo (between-group difference, 2.0%, P = .003, and 3.8%, P = .002, respectively). Percentage change from baseline in femoral neck BMD at Month 24 was significantly higher with ZOL than with placebo (3.8%, P = .003). The BMD benefit was comparable with that observed in women in this study. New clinical fractures occurred in 36 (7.1%) participants (ZOL, n = 16; placebo, n = 20; P = .64). The ZOL safety profile was comparable with that of placebo, with no significant differences in cardiovascular or long-term renal function and a trend toward lower mortality in ZOL-treated men., Conclusion: Once-yearly IV ZOL 5 mg increases bone mass at the hip and femoral neck in men within 90 days of repair of a low-trauma hip fracture. Increases were of a similar magnitude to those observed in women in the same study., (© 2011, Copyright the Authors Journal compilation © 2011, The American Geriatrics Society.)
- Published
- 2011
- Full Text
- View/download PDF